VLP-encapsulated TLR9 Agonist CMP-001

DRUG2 trials

Sponsors

University of Southern California, National Cancer Institute (NCI)

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8Locally Advanced Malignant Solid NeoplasmMelanoma of Unknown PrimaryMetastatic Pancreatic AdenocarcinomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Recurrent Cutaneous Melanoma

Phase 1

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

TerminatedNCT04387071

University of Southern CaliforniaLocally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 +1

Start: 2021-04-29End: 2022-12-28Updated: 2026-04-17

Phase 2

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Active, not recruitingNCT04708418

National Cancer Institute (NCI)Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 +3

Start: 2021-10-15End: 2026-12-31Target: 60Updated: 2026-08-04

Related Papers

A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.

Journal of Clinical Oncology2025-06-041 citations

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts2022-11-014 citations

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2022-10-0187 citations